XERAVA™ (eravacycline) for injection is a novel fluorocycline of the tetracycline class of antibacterials that is approved by the FDA for the treatment of complicated intra-abdominal infections (cIAI) in patients 18 years of age and older. XERAVA™ is approved by the European Commission for the treatment of cIAI in adults. Prescribing information for XERAVA™ is available at www.xerava.com. XERAVA™ is marketed in the U.S. by Tetraphase Pharmaceuticals, Inc., a wholly owned subsidiary of La Jolla, and will be marketed in Europe by PAION.